Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Congratulations to Dr Bart Cornelissen of the CRUK/MRC Oxford Institute for Radiation Oncology, Department of Oncology who has secured a £200k grant from UK medical research charity, Pancreatic Cancer Research Fund (PCRF).

None

Similar stories

Reprogramming tumour cells using an antimalarial drug

Research

Results from the ATOM clinical trial at the University of Oxford have shown that the anti-malarial drug Atovaquone can reduce very low oxygen tumour environments. This has the potential to make cancers behave less aggressively and to improve the impact of everyday cancer treatments.

Hidden lung damage from COVID-19 revealed in new study

Research Translational Research

Early findings from a study into longer-term damage amongst patients recovering from COVID-19 suggest that the use of cutting-edge scanning techniques may detect previously unseen lung damage.

Oxfordshire-based SCAN pathway wins BMJ award

Innovation Research

A pathway designed to investigate individuals with non-specific but concerning symptoms of cancer wins the BMJ Awards 2020 Cancer Care Team of the Year.

Tackling the serious side effects of cancer treatment in an ageing population

Publication Research

Prof. Anne Kiltie and her team discuss their important work into the effects of radiosensitisation on ageing cancer patients with the CRUK Science Blog.

New digital classification method using AI developed for colorectal cancer

Artificial Intelligence Research Translational Research

Understanding the molecular subtype of a cancer is becoming an importance part of the diagnostic process as it helps a doctor better understand a patient’s prognosis, determine the best course of action for treatment and helps researchers devise new, more-efficient, precision therapies.